Innate Historical Balance Sheet

IPHA Stock  USD 2.09  0.03  1.42%   
Trend analysis of Innate Pharma balance sheet accounts such as Other Current Liabilities of 14.8 M or Total Current Liabilities of 48.6 M provides information on Innate Pharma's total assets, liabilities, and equity, which is the actual value of Innate Pharma to its prevalent stockholders. By breaking down trends over time using Innate Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Innate Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Innate Pharma is a good buy for the upcoming year.

Innate Pharma Inventory

(2.88 Million)

  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.

About Innate Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Innate Pharma at a specified time, usually calculated after every quarter, six months, or one year. Innate Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Innate Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Innate currently owns. An asset can also be divided into two categories, current and non-current.

Innate Pharma Balance Sheet Chart

At present, Innate Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 48.6 M, whereas Total Assets are forecasted to decline to about 188 M.

Total Assets

Total assets refers to the total amount of Innate Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Innate Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Innate Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Innate Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.
Most accounts from Innate Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.At present, Innate Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 48.6 M, whereas Total Assets are forecasted to decline to about 188 M.
 2022 2023 2024 2025 (projected)
Short and Long Term Debt Total42.3M39.9M45.9M48.2M
Total Assets207.9M184.2M211.8M188.0M

Innate Pharma balance sheet Correlations

0.120.790.90.860.770.8-0.83-0.320.760.920.870.390.890.620.560.40.70.040.570.940.760.950.010.610.55
0.12-0.050.00.040.22-0.380.33-0.89-0.160.00.190.580.010.640.72-0.040.270.90.810.160.370.060.650.69-0.19
0.79-0.050.810.630.350.74-0.63-0.10.880.660.550.350.710.330.260.540.51-0.030.320.780.350.84-0.110.320.69
0.90.00.810.790.650.85-0.72-0.140.660.760.780.070.690.410.330.180.44-0.080.40.840.620.860.030.40.79
0.860.040.630.790.780.6-0.77-0.180.540.830.90.270.720.530.420.070.32-0.150.510.650.720.73-0.020.510.43
0.770.220.350.650.780.49-0.63-0.370.390.740.850.240.620.670.61-0.040.450.00.570.650.960.610.160.660.25
0.8-0.380.740.850.60.49-0.860.190.780.780.58-0.050.770.130.050.430.53-0.350.040.810.420.84-0.270.110.67
-0.830.33-0.63-0.72-0.77-0.63-0.86-0.13-0.73-0.94-0.66-0.14-0.91-0.29-0.19-0.41-0.550.39-0.14-0.74-0.54-0.830.28-0.26-0.38
-0.32-0.89-0.1-0.14-0.18-0.370.19-0.13-0.03-0.17-0.34-0.6-0.19-0.8-0.86-0.1-0.49-0.84-0.92-0.37-0.53-0.27-0.39-0.830.06
0.76-0.160.880.660.540.390.78-0.73-0.030.720.530.460.830.240.20.790.7-0.130.210.80.330.82-0.180.230.44
0.920.00.660.760.830.740.78-0.94-0.170.720.760.350.970.530.460.430.67-0.090.430.840.70.9-0.070.510.34
0.870.190.550.780.90.850.58-0.66-0.340.530.760.370.680.610.530.120.47-0.050.580.730.80.680.170.590.34
0.390.580.350.070.270.24-0.05-0.14-0.60.460.350.370.480.550.60.620.620.50.620.410.310.360.410.57-0.24
0.890.010.710.690.720.620.77-0.91-0.190.830.970.680.480.490.440.650.79-0.030.410.870.590.91-0.090.480.28
0.620.640.330.410.530.670.13-0.29-0.80.240.530.610.550.490.980.120.590.50.840.590.820.550.311.00.07
0.560.720.260.330.420.610.05-0.19-0.860.20.460.530.60.440.980.140.630.610.860.570.770.50.380.990.03
0.4-0.040.540.180.07-0.040.43-0.41-0.10.790.430.120.620.650.120.140.750.080.10.55-0.030.52-0.10.12-0.01
0.70.270.510.440.320.450.53-0.55-0.490.70.670.470.620.790.590.630.750.330.510.850.520.760.030.590.14
0.040.9-0.03-0.08-0.150.0-0.350.39-0.84-0.13-0.09-0.050.5-0.030.50.610.080.330.730.150.20.090.40.55-0.07
0.570.810.320.40.510.570.04-0.14-0.920.210.430.580.620.410.840.860.10.510.730.530.70.50.340.880.12
0.940.160.780.840.650.650.81-0.74-0.370.80.840.730.410.870.590.570.550.850.150.530.670.960.030.590.55
0.760.370.350.620.720.960.42-0.54-0.530.330.70.80.310.590.820.77-0.030.520.20.70.670.630.220.810.24
0.950.060.840.860.730.610.84-0.83-0.270.820.90.680.360.910.550.50.520.760.090.50.960.63-0.090.540.61
0.010.65-0.110.03-0.020.16-0.270.28-0.39-0.18-0.070.170.41-0.090.310.38-0.10.030.40.340.030.22-0.090.33-0.17
0.610.690.320.40.510.660.11-0.26-0.830.230.510.590.570.481.00.990.120.590.550.880.590.810.540.330.07
0.55-0.190.690.790.430.250.67-0.380.060.440.340.34-0.240.280.070.03-0.010.14-0.070.120.550.240.61-0.170.07
Click cells to compare fundamentals

Innate Pharma Account Relationship Matchups

Innate Pharma balance sheet Accounts

202020212022202320242025 (projected)
Total Assets307.4M267.5M207.9M184.2M211.8M188.0M
Short Long Term Debt Total19.1M44.3M42.3M39.9M45.9M48.2M
Other Current Liab14.3M14.4M13.0M15.1M17.4M14.8M
Total Current Liabilities46.7M79.9M41.3M39.6M45.6M48.6M
Total Stockholder Equity156.0M107.4M54.2M51.9M59.7M81.7M
Property Plant And Equipment Net11.7M10.2M8.5M6.3M7.3M7.9M
Current Deferred Revenue12.5M12.5M6.6M5.9M6.7M6.4M
Net Debt(117.7M)(59.5M)(42.0M)(30.7M)(27.6M)(29.0M)
Retained Earnings(220.5M)(272.2M)(330.3M)(336.9M)(303.2M)(288.0M)
Accounts Payable20.7M14.7M13.7M8.6M9.8M17.0M
Cash136.8M103.8M84.2M70.6M81.2M84.5M
Non Current Assets Total134.1M129.2M68.0M36.2M41.6M55.5M
Non Currrent Assets Other30.1M30.0M14.2M19.6M22.6M23.7M
Cash And Short Term Investments151.6M119.8M101.5M92.5M106.3M106.4M
Common Stock Shares Outstanding78.9M79.5M79.6M80.5M92.5M53.1M
Short Term Investments14.8M16.1M17.3M21.9M19.7M16.8M
Liabilities And Stockholders Equity307.4M267.5M207.9M184.2M211.8M188.0M
Non Current Liabilities Total104.8M80.2M112.4M92.7M106.6M57.7M
Other Current Assets12.3M17.6M35.3M40.3M46.4M48.7M
Other Stockholder Equity372.1M375.2M379.6M384.3M441.9M464.0M
Total Liab151.4M160.1M153.7M132.3M152.1M106.3M
Property Plant And Equipment Gross11.7M11.7M10.2M8.5M9.8M8.0M
Total Current Assets173.3M138.3M139.8M148.0M170.2M132.5M
Short Term Debt2.1M30.7M2.1M8.9M10.3M10.8M
Common Stock4.0M4.0M4.0M4.0M4.7M2.8M
Net Receivables10.6M846K3.1M15.2M17.5M21.7M
Accumulated Other Comprehensive Income355K456K819K495K569.3K597.7K
Inventory1.0(4.9M)(2K)(3.4M)(3.0M)(2.9M)
Intangible Assets46.3M44.2M42.6M416K478.4K454.5K
Other Liab45.5M87.8M66.7M72.2M65.0M74.7M
Net Tangible Assets120.4M109.7M63.2M52.6M60.5M84.3M
Long Term Debt16.9M13.5M38.9M30.6M35.2M37.0M
Capital Lease Obligations3.5M2.8M2.1M835K751.5K713.9K
Long Term Investments38.9M39.9M35.1M9.8M8.8M8.4M
Short Long Term Debt2.1M30.7M1.3M8.5M9.7M5.6M
Non Current Liabilities Other44.9M33.0M53.0M45.0M51.8M54.4M
Property Plant Equipment11.7M11.7M10.2M8.5M9.8M10.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.75)
Earnings Share
(0.44)
Revenue Per Share
0.419
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.14)
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.